76 results on '"Tsuruga T"'
Search Results
2. Multifunctional transcription factor TFII-I is an activator of BRCA1 function.
- Author
-
Tanikawa, M., Wada-Hiraike, O., Nakagawa, S., Shirane, A., Hiraike, H., Koyama, S., Miyamoto, Y., Sone, K., Tsuruga, T., Nagasaka, K., Matsumoto, Y., Ikeda, Y., Shoji, K., Oda, K., Fukuhara, H., Nakagawa, K., Kato, S., Yano, T., and Taketani, Y.
- Subjects
TRANSCRIPTION factors ,BRCA genes ,NUCLEOTIDE sequence ,TRANSFORMING growth factors ,WILLIAMS syndrome ,PATHOLOGICAL physiology ,CELL physiology ,GENETICS - Abstract
Background: The TFII-I is a multifunctional transcriptional factor known to bind specifically to several DNA sequence elements and to mediate growth factor signalling. A microdeletion at the chromosomal location 7q11.23 encoding TFII-I and the related family of transcription factors may result in the onset of Williams-Beuren syndrome, an autosomal dominant genetic disorder characterised by a unique cognitive profile, diabetes, hypertension, anxiety, and craniofacial defects. Hereditary breast and ovarian cancer susceptibility gene product BRCA1 has been shown to serve as a positive regulator of SIRT1 expression by binding to the promoter region of SIRT1, but cross talk between BRCA1 and TFII-I has not been investigated to date.Methods: A physical interaction between TFII-I and BRCA1 was explored. To determine pathophysiological function of TFII-I, its role as a transcriptional cofactor for BRCA1 was investigated.Results: We found a physical interaction between the carboxyl terminus of TFII-I and the carboxyl terminus of BRCA1, also known as the BRCT domain. Endogenous TFII-I and BRCA1 form a complex in nuclei of intact cells and formation of irradiation-induced nuclear foci was observed. We also showed that the expression of TFII-I stimulates the transcriptional activation function of BRCT by a transient expression assay. The expression of TFII-I also enhanced the transcriptional activation of the SIRT1 promoter mediated by full-length BRCA1.Conclusion: These results revealed the intrinsic mechanism that TFII-I may modulate the cellular functions of BRCA1, and provide important implications to understand the development of breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
3. Identification of DBC1 as a transcriptional repressor for BRCA1.
- Author
-
Hiraike, H., Wada-Hiraike, O., Nakagawa, S., Koyama, S., Miyamoto, Y., Sone, K., Tanikawa, M., Tsuruga, T., Nagasaka, K., Matsumoto, Y., Oda, K., Shoji, K., Fukuhara, H., Saji, S., Nakagawa, K., Kato, S., Yano, T., and Taketani, Y.
- Subjects
BREAST cancer ,TUMOR suppressor genes ,APOPTOSIS ,TRANSCRIPTION factors ,CELL death - Abstract
Background: DBC1/KIAA1967 (deleted in breast cancer 1) is a putative tumour-suppressor gene cloned from a heterozygously deleted region in breast cancer specimens. Caspase-dependent processing of DBC1 promotes apoptosis, and depletion of endogenous DBC1 negatively regulates p53-dependent apoptosis through its specific inhibition of SIRT1. Hereditary breast and ovarian cancer susceptibility gene product BRCA1, by binding to the promoter region of SIRT1, is a positive regulator of SIRT1 expression.Methods: A physical interaction between DBC1 and BRCA1 was investigated both in vivo and in vitro. To determine the pathophysiological significance of DBC1, its role as a transcriptional factor was studied.Results: We found a physical interaction between the amino terminus of DBC1 and the carboxyl terminus of BRCA1, also known as the BRCT domain. Endogenous DBC1 and BRCA1 form a complex in the nucleus of intact cells, which is exported to the cytoplasm during ultraviolet-induced apoptosis. We also showed that the expression of DBC1 represses the transcriptional activation function of BRCT by a transient expression assay. The expression of DBC1 also inhibits the transactivation of the SIRT1 promoter mediated by full-length BRCA1.Conclusion: These results revealed that DBC1 may modulate the cellular functions of BRCA1 and have important implications in the understanding of carcinogenesis in breast tissue. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
4. Comorbid thrombosis as an adverse prognostic factor in patients with ovarian clear cell carcinoma regardless of staging.
- Author
-
Yamaguchi K, Tsuruga T, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Iriyama T, Matsumoto Y, Hiraike O, Hirota Y, Fujii T, and Osuga Y
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Aged, Prognosis, Adult, Comorbidity, Aged, 80 and over, Survival Rate, Progression-Free Survival, Ovarian Neoplasms pathology, Ovarian Neoplasms mortality, Ovarian Neoplasms complications, Thrombosis pathology, Neoplasm Staging, Adenocarcinoma, Clear Cell pathology, Adenocarcinoma, Clear Cell mortality, Adenocarcinoma, Clear Cell complications
- Abstract
Objective: Patients with ovarian clear cell carcinoma (OCCC) often present with thrombosis. While cancer patients with concomitant thrombosis were generally reported to have worse prognoses than those without, the association between thrombosis and prognosis has not been elucidated in OCCC. This study aimed to determine how the co-occurrence of thrombosis affects OCCC prognoses., Methods: We retrospectively examined 115 patients with OCCC who were diagnosed and treated at the University of Tokyo Hospital between 2009 and 2019., Results: Of 115 patients with OCCC, thrombosis was present in 12.5% of 80 patients and in 42.8% of 35 patients who had OCCC stage I/II and stage III/IV, respectively. In stage I/II, the 5-year progression-free survival was 20.6% and 91.8% among patients with thrombosis and among those without, respectively, while the corresponding 5-year overall survival rates were 50.0% and 94.1%. Therefore, the outcomes were significantly poorer among patients with thrombosis (p < 0.0001 and p < 0.0001, respectively). In stage III/IV, the 5-year progression-free survival was 26.7% and 52.8% among patients with thrombosis and among those without, respectively, while the corresponding 5-year overall survival rates were 32.0% and 62.2%. Similarly, the outcomes were significantly poorer among patients with thrombosis (p = 0.0139 and p = 0.369, respectively)., Conclusion: We determined that thrombosis is more likely to develop in advanced OCCC stages than in early stages, and its co-occurrence is associated with a poor prognosis, regardless of disease stage., (© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Role of microbiota-derived corisin in coagulation activation during SARS-CoV-2 infection.
- Author
-
Tsuruga T, Fujimoto H, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Ito T, Tomaru A, Saiki H, Okano T, Alhawsawi MAB, Takeshita A, Nishihama K, Takei R, Kondoh Y, Cann I, Gabazza EC, and Kobayashi T
- Subjects
- Humans, Animals, Male, Female, Middle Aged, Cross-Sectional Studies, Mice, A549 Cells, Acute Lung Injury microbiology, Acute Lung Injury blood, THP-1 Cells, Aged, Disease Models, Animal, Microbiota, Dysbiosis, Adult, Antithrombin III, Mice, Inbred C57BL, Peptide Hydrolases, COVID-19 blood, COVID-19 complications, COVID-19 immunology, Blood Coagulation, SARS-CoV-2, Human Umbilical Vein Endothelial Cells
- Abstract
Background: Coagulopathy is a major cause of morbidity and mortality in COVID-19 patients. Hypercoagulability in COVID-19 results in deep vein thrombosis, thromboembolic complications, and diffuse intravascular coagulation. Microbiome dysbiosis influences the clinical course of COVID-19. However, the role of dysbiosis in COVID-19-associated coagulopathy is not fully understood., Objectives: The present study tested the hypothesis that the microbiota-derived proapoptotic corisin is involved in the coagulation system activation during SARS-CoV-2 infection., Methods: This cross-sectional study included 47 consecutive patients who consulted for symptoms of COVID-19. A mouse acute lung injury model was used to recapitulate the clinical findings. A549 alveolar epithelial, THP-1, and human umbilical vein endothelial cells were used to evaluate procoagulant and anticoagulant activity of corisin., Results: COVID-19 patients showed significantly high circulating levels of corisin, thrombin-antithrombin complex, D-dimer, tumor necrosis factor-α, and monocyte-chemoattractant protein-1 with reduced levels of free protein S compared with healthy subjects. The levels of thrombin-antithrombin complex, D-dimer, and corisin were significantly correlated. A monoclonal anticorisin-neutralizing antibody significantly inhibited the inflammatory response and coagulation system activation in a SARS-CoV-2 spike protein-associated acute lung injury mouse model, and the levels of corisin and thrombin-antithrombin complex were significantly correlated. In an in vitro experiment, corisin increased the tissue factor activity and decreased the anticoagulant activity of thrombomodulin in epithelial, endothelial, and monocytic cells., Conclusion: The microbiota-derived corisin is significantly increased and correlated with activation of the coagulation system during SARS-CoV-2 infection, and corisin may directly increase the procoagulant activity in epithelial, endothelial, and monocytic cells., Competing Interests: Declaration of competing interests E.C.G., C.N.D.'A.-G., and I.C. hold patents on corisin and the anticorisin monoclonal antibody reported in this study. The other authors declare no competing interests related to this manuscript., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.
- Author
-
Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, and Osuga Y
- Subjects
- Female, Humans, Fluorescent Dyes metabolism, Optical Imaging methods, Glutathione, Ovary metabolism, Carcinoma
- Abstract
The purpose of this study is to clarify the metabolic dependence of ovarian clear cell carcinoma (CCC) by comparing normal tissues and to examine the applicability of fluorescence imaging probe to exploit these metabolic differences. Enhanced glutathione synthesis was supported by the increased uptake of related metabolites and elevated expression levels of genes. Accumulation of intracellular iron and lipid peroxide, induction of cell death by inhibition of the glutathione synthesis pathway indicated that ferroptosis was induced. The activation of γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), a fluorescent imaging probe that recognizes γ-glutamyl transferase, which is essential for the synthesis of glutathione, was investigated in fresh-frozen surgical specimens. gGlu-HMRG detected extremely strong fluorescent signals in the tumor lesions of CCC patients, compared to normal ovaries or endometrium. These results revealed that CCC occurs in the stressful and unique environment of free radical-rich endometrioma, and that glutathione metabolism is enhanced as an adaptation to oxidative stress. Furthermore, a modality that exploits these metabolic differences would be useful for distinguishing between CCC and normal tissues., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
7. Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions.
- Author
-
Nishii Y, Sakaguchi T, Esumi S, Esumi M, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Yasui H, Ito A, Tarukawa T, Tsuruga T, D'Alessandro-Gabazza CN, Yasuma T, Fujimoto H, Asano F, Gabazza EC, Kobayashi T, Taguchi O, and Hataji O
- Subjects
- Humans, Male, Biopsy, Endosonography, Foreskin, Genetic Testing, Bronchoscopy
- Abstract
Bronchoscopy with radial-probe endobronchial ultrasound, a guide sheath, and electromagnetic navigation can improve the diagnostic yield of peripheral lung nodules. However, the suitability of specimens for genetic analysis remains unsatisfactory. We hypothesized that a transbronchial biopsy performed after closely approaching the bronchoscope tip to the lesion might provide more suitable specimens for genetic analysis. We enrolled 155 patients with peripheral pulmonary lesions who underwent bronchoscopy with a thin or ultrathin bronchoscope. Bronchoscopy was performed using virtual bronchoscopic navigation and radial-probe endobronchial ultrasound with a guide sheath. The bronchoscope tip was placed closer to the lesion during bronchoscopy to collect larger specimens with higher malignant cell content. The patients who underwent a close-to-lesion biopsy had higher rates of overall diagnostic yield, histopathological diagnostic yield, and specimen quality for genetic testing than those who did not. The significant determinants of the specimen's suitability were the close-to-lesion approach, within-the-lesion image, the use of standard 1.9-mm-forceps, and the number of cancer-cell-positive specimens. The significant predictors of the specimen's suitability for genetic analysis were close-to-lesion biopsy and the number of malignant cell-positive tissue samples. This study demonstrates that the close-to-lesion transbronchial biopsy significantly improves the suitability of bronchoscopic specimens for genetic analysis., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
8. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin.
- Author
-
Nara K, Taguchi A, Yamamoto T, Tsuruga T, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Takada T, Suzuki H, and Osuga Y
- Subjects
- Female, Humans, Antibiotics, Antineoplastic therapeutic use, Retrospective Studies, Quality of Life, Neoplasm Recurrence, Local drug therapy, Doxorubicin therapeutic use, Polyethylene Glycols therapeutic use, Dexamethasone therapeutic use, Primary Prevention, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hand-Foot Syndrome etiology, Hand-Foot Syndrome prevention & control, Hand-Foot Syndrome drug therapy, Ovarian Neoplasms drug therapy
- Abstract
Purpose: Pegylated liposomal doxorubicin (PLD)-induced hand-foot syndrome (HFS) frequently lowers the quality of life of ovarian cancer patients. Wrist and ankle cooling, having a limited preventive effect, has been the commonest supportive HFS care. In this study, we retrospectively assessed the primary preventive effect of a combination of regional cooling and oral dexamethasone therapy (cooling + oral Dex) on HFS., Methods: This study is a single-arm retrospective, observational study. Recurrent ovarian cancer patients were administered PLD ± bevacizumab. We retrospectively examined the efficacy of hands and feet cooling (from the start of PLD to the end) + oral Dex (day 1-5: 8 mg/day, day 6, 7: 4 mg/day) for primary HFS prevention., Results: This study included 74 patients. The initial dose of PLD was 50 mg/m
2 and 40 mg/m2 for 32 (43.2%) and 42 (56.8%) patients, respectively. HFS of Grade ≥ 2 and Grade ≥ 3 developed in five (6.8%) and one (1.4%) patient(s), respectively. The incidence of ≥ Grade 2 and ≥ Grade 3 HFS was much lower than those reported in previous studies. Dose reduction was required in 13 patients (17.6%) mainly because of neutropenia or mucositis; there was no HFS-induced dose reduction. Meanwhile, PLD therapy was discontinued mainly because of interstitial pneumonia (4 patients) and HFS (one patient)., Conclusions: We demonstrated the efficacy of regional cooling and oral Dex for primary prevention of PLD-induced HFS. Although future prospective studies are needed to confirm its efficacy, this combination therapy can be considered for primary prevention of HFS in ovarian cancer patients on PLD., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
9. Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression.
- Author
-
Inoue R, Yasuma T, Fridman D'Alessandro V, Toda M, Ito T, Tomaru A, D'Alessandro-Gabazza CN, Tsuruga T, Okano T, Takeshita A, Nishihama K, Fujimoto H, Kobayashi T, and Gabazza EC
- Subjects
- Mice, Humans, Animals, Lung pathology, Bleomycin adverse effects, Mice, Transgenic, Fibrosis, Mice, Inbred C57BL, Matrix Metalloproteinase 2 genetics, Matrix Metalloproteinase 2 metabolism, Idiopathic Pulmonary Fibrosis metabolism
- Abstract
Idiopathic pulmonary fibrosis is a progressive and fatal disease with a poor prognosis. Matrix metalloproteinase-2 is involved in the pathogenesis of organ fibrosis. The role of matrix metalloproteinase-2 in lung fibrosis is unclear. This study evaluated whether overexpression of matrix metalloproteinase-2 affects the development of pulmonary fibrosis. Lung fibrosis was induced by bleomycin in wild-type mice and transgenic mice overexpressing human matrix metalloproteinase-2. Mice expressing human matrix metalloproteinase-2 showed significantly decreased infiltration of inflammatory cells and inflammatory and fibrotic cytokines in the lungs compared to wild-type mice after induction of lung injury and fibrosis with bleomycin. The computed tomography score, Ashcroft score of fibrosis, and lung collagen deposition were significantly reduced in human matrix metalloproteinase transgenic mice compared to wild-type mice. The expression of anti-apoptotic genes was significantly increased, while caspase-3 activity was significantly reduced in the lungs of matrix metalloproteinase-2 transgenic mice compared to wild-type mice. Active matrix metalloproteinase-2 significantly decreased bleomycin-induced apoptosis in alveolar epithelial cells. Matrix metalloproteinase-2 appears to protect against pulmonary fibrosis by inhibiting apoptosis of lung epithelial cells.
- Published
- 2023
- Full Text
- View/download PDF
10. Application of organoid culture from HPV18-positive small cell carcinoma of the uterine cervix for precision medicine.
- Author
-
Kusakabe M, Taguchi A, Tanikawa M, Hoshi D, Tsuchimochi S, Qian X, Toyohara Y, Kawata A, Wagatsuma R, Yamaguchi K, Yamamoto Y, Ikemura M, Sone K, Mori-Uchino M, Matsunaga H, Tsuruga T, Nagamatsu T, Kukimoto I, Wada-Hiraike O, Kawazu M, Ushiku T, Takeyama H, Oda K, Kawana K, Hippo Y, and Osuga Y
- Subjects
- Female, Humans, Animals, Mice, Human papillomavirus 18 genetics, Precision Medicine, Proto-Oncogene Proteins p21(ras) genetics, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell genetics, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms genetics, Uterine Cervical Neoplasms pathology, Papillomavirus Infections complications, Papillomavirus Infections drug therapy, Papillomavirus Infections pathology, Small Cell Lung Carcinoma, Lung Neoplasms
- Abstract
Background: Small cell carcinoma of the uterine cervix (SCCC) is a rare and highly malignant human papillomavirus (HPV)-associated cancer in which human genes related to the integration site can serve as a target for precision medicine. The aim of our study was to establish a workflow for precision medicine of HPV-associated cancer using patient-derived organoid., Methods: Organoid was established from the biopsy of a patient diagnosed with HPV18-positive SCCC. Therapeutic targets were identified by whole exome sequencing (WES) and RNA-seq analysis. Drug sensitivity testing was performed using organoids and organoid-derived mouse xenograft model., Results: WES revealed that both the original tumor and organoid had 19 somatic variants in common, including the KRAS p.G12D pathogenic variant. Meanwhile, RNA-seq revealed that HPV18 was integrated into chromosome 8 at 8q24.21 with increased expression of the proto-oncogene MYC. Drug sensitivity testing revealed that a KRAS pathway inhibitor exerted strong anti-cancer effects on the SCCC organoid compared to a MYC inhibitor, which were also confirmed in the xenograft model., Conclusion: In this study, we confirmed two strategies for identifying therapeutic targets of HPV-derived SCCC, WES for identifying pathogenic variants and RNA sequencing for identifying HPV integration sites. Organoid culture is an effective tool for unveiling the oncogenic process of rare tumors and can be a breakthrough for the development of precision medicine for patients with HPV-positive SCCC., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
11. Effect of pelvic radiotherapy on patients with stage IB‑IIA cervical cancer after radical hysterectomy: A single‑center retrospective study.
- Author
-
Ishizawa C, Taguchi A, Tanikawa M, Honjo H, Nishijima A, Eguchi S, Miyamoto Y, Sone K, Tsuruga T, Mori M, and Osuga Y
- Abstract
The effects of post-operative adjuvant radiotherapy (RT) on intermediate-risk patients with cervical cancer have not been fully elucidated. Therefore, the present study aimed to investigate the impact of RT on intermediate-risk cervical cancer. The data of 112 patients with stage IB and IIA cervical cancer treated with radical hysterectomy between January 2009 and December 2018 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the frequency of adverse events were compared between patients with and without adjuvant RT (RT
+ and RT- , respectively). Subgroup analyses of PFS based on tumor size, cervical stromal invasion, lymphovascular space invasion and histology [squamous cell carcinoma (SCC) vs. non-SCC] were performed. Among the 112 patients, 41 received adjuvant RT. Although there were no significant differences in OS or PFS between the RT+ and RT- groups, the frequency of adverse events was much higher in the RT+ group. Patients in the RT+ group also had more recurrent risk factors than those in the RT- group. Based on the subgroup analyses, although no significant differences were observed between any of the groups, RT demonstrated a different impact on PFS between SCC and non-SCC: No difference was observed in the SCC group, whereas patients in the RT+ group tended to have poorer prognoses compared to those in the RT- group of the non-SCC group. These results suggest that the impact of post-operative RT on stage IB and IIA cervical cancer is limited and is accompanied by increased adverse events. The eligibility of patients for post-operative RT should be carefully determined based on the therapeutic effect of RT in each subgroup., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Ishizawa et al.)- Published
- 2023
- Full Text
- View/download PDF
12. Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases.
- Author
-
Toyohara Y, Sone K, Noda K, Yoshida K, Kurokawa R, Tanishima T, Kato S, Inui S, Nakai Y, Ishida M, Gonoi W, Tanimoto S, Takahashi Y, Inoue F, Kukita A, Kawata Y, Taguchi A, Furusawa A, Miyamoto Y, Tsukazaki T, Tanikawa M, Iriyama T, Mori-Uchino M, Tsuruga T, Oda K, Yasugi T, Takechi K, Abe O, and Osuga Y
- Subjects
- Female, Humans, Diagnosis, Differential, Sensitivity and Specificity, Deep Learning, Uterine Neoplasms diagnostic imaging, Uterine Neoplasms pathology, Leiomyoma pathology, Sarcoma diagnostic imaging, Sarcoma pathology, Soft Tissue Neoplasms diagnosis, Pelvic Neoplasms
- Abstract
Uterine sarcomas have very poor prognoses and are sometimes difficult to distinguish from uterine leiomyomas on preoperative examinations. Herein, we investigated whether deep neural network (DNN) models can improve the accuracy of preoperative MRI-based diagnosis in patients with uterine sarcomas. Fifteen sequences of MRI for patients (uterine sarcoma group: n = 63; uterine leiomyoma: n = 200) were used to train the models. Six radiologists (three specialists, three practitioners) interpreted the same images for validation. The most important individual sequences for diagnosis were axial T2-weighted imaging (T2WI), sagittal T2WI, and diffusion-weighted imaging. These sequences also represented the most accurate combination (accuracy: 91.3%), achieving diagnostic ability comparable to that of specialists (accuracy: 88.3%) and superior to that of practitioners (accuracy: 80.1%). Moreover, radiologists' diagnostic accuracy improved when provided with DNN results (specialists: 89.6%; practitioners: 92.3%). Our DNN models are valuable to improve diagnostic accuracy, especially in filling the gap of clinical skills between interpreters. This method can be a universal model for the use of deep learning in the diagnostic imaging of rare tumors., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. Pt-embodiment ZIF-67-derived nanocage as enhanced immunoassay for infectious virus detection.
- Author
-
Khoris IM, Kenta T, Ganganboina AB, and Park EY
- Subjects
- Cobalt, Immunoassay, Oxides, Platinum chemistry, Biosensing Techniques, Metal Nanoparticles chemistry
- Abstract
A facile and general strategy has been employed to develop highly-active nanozyme for immunoassay purposes. The hollow nanostructure of the Co
3 O4 nanocages (NCs) was anchoring the platinum nanoparticles (PtNPs) enclosed by the exposed oxides framework nd formed PtNPs@Co3 O4 NCs. The embodiment of PtNPs was considered an ideal hybrid nanozyme that efficiently catalyzed the oxidation of the substrate molecules with enhanced activity. The PtNPs@Co3 O4 NCs were revisited and repurposed on showing its nanozyme's activity with optimization done for the immunoassay platform. The embodiment of 32.44% Pt in the hollow nanostructures demonstrated the highest signal-to-noise responses in the immunoassay. In addition, the stepwise analysis highlighted the enhancement factor of the nanocages' catalytic mechanism. Based on their catalytic activity, these nanocages have been demonstrated to enable sub-femtogram level biosensing of norovirus-like particles (NoV-LPs) with highly selective signals in the capture-detect immunoassay format. The detection limit of the prepared immunoassay achieved 33.52 viral NoV copies/mL of the detection limit, which is 321-folds lower magnitude of the commercial ELISA. This nanocage's enhanced synergic catalytic properties could have great potential applications, including catalysis, biological labeling, and bioassays., Competing Interests: Declaration of competing interest The authors declare that they have no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
14. Manual vacuum aspiration (women's MVA) for endometrial biopsy for patients with suspected endometrial malignancies.
- Author
-
Saito E, Matsumoto Y, Nitta S, Fujino S, Tsuruga T, Mori-Uchino M, Iwase H, Kasamatsu T, Kugu K, and Osuga Y
- Subjects
- Humans, Female, Vacuum Curettage adverse effects, Endometrium pathology, Biopsy, Endometrial Neoplasms pathology, Uterine Neoplasms pathology
- Abstract
Aim: Endometrial biopsy is generally performed with a metal uterine curette sonde; however, recently, many types of vacuum aspirators are available, including the manual vacuum aspiration (MVA) system. We used the women's MVA system for endometrial sampling and evaluated its effectiveness in determining the presence of endometrial malignancy., Methods: Forty-seven samples were examined using the following procedures after measuring endometrial thickness by transvaginal ultrasonography: fractional curettage biopsy (Bx; 20 samples), total curettage under general anesthesia (T/C; 13 samples), and MVA (14 samples). The quality of the endometrial samples was classified into four types: 1-4, where 1 denoted poor and 4, good quality., Results: The mean score of the MVA group was significantly higher than that of the partial curettage biopsy group (p = 0.0065). No differences were observed between the MVA and total curettage groups (p = 1.00). When patients were divided into two groups according to endometrial thickness (<10 mm or ≥10 mm) and analyzed, both the MVA and T/C groups did not show a significant difference in their scores compared to the Bx group when the endometrial thickness was <10 mm. However, when the endometrial thickness was ≥10 mm, the MVA and T/C groups had significantly better scores than the Bx group (p = 0.0225 and p = 0.0244, respectively). Vagal reflex, as an adverse event, was observed only in two patients in the Bx group (2/20, 10%)., Conclusion: Considering its quality and safety, Karman-type MVA for endometrial sampling could be an alternative to fractional curettage using a metallic uterine curette sonde., (© 2022 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.)
- Published
- 2022
- Full Text
- View/download PDF
15. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
- Author
-
Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, Tanimoto S, Taguchi A, Fukuda T, Miyamoto Y, Tanikawa M, Mori-Uchino M, Tsuruga T, Iriyama T, Matsumoto Y, Nagasaka K, Wada-Hiraike O, Oda K, Hamamoto R, and Osuga Y
- Abstract
The histone methyltransferase SET domain-containing protein 8 (SETD8), which methylates histone H4 lysine 20 (H4K20) and non-histone proteins such as p53, plays key roles in human carcinogenesis. Our aim was to determine the involvement of SETD8 in endometrial cancer and its therapeutic potential and identify the downstream genes regulated by SETD8 via H4K20 methylation and the p53 signaling pathway. We examined the expression profile of SETD8 and evaluated whether SETD8 plays a critical role in the proliferation of endometrial cancer cells using small interfering RNAs (siRNAs). We identified the prognostically important genes regulated by SETD8 via H4K20 methylation and p53 signaling using chromatin immunoprecipitation sequencing, RNA sequencing, and machine learning. We confirmed that SETD8 expression was elevated in endometrial cancer tissues. Our in vitro results suggest that the suppression of SETD8 using siRNA or a selective inhibitor attenuated cell proliferation and promoted the apoptosis of endometrial cancer cells. In these cells, SETD8 regulates genes via H4K20 methylation and the p53 signaling pathway. We also identified the prognostically important genes related to apoptosis, such as those encoding KIAA1324 and TP73, in endometrial cancer. SETD8 is an important gene for carcinogenesis and progression of endometrial cancer via H4K20 methylation.
- Published
- 2022
- Full Text
- View/download PDF
16. MED1, a novel binding partner of BRCA1, regulates homologous recombination and R-loop processing.
- Author
-
Honjoh H, Tanikawa M, Wada-Hiraike O, Oda K, Inaba H, Kukita A, Kawata Y, Kusakabe M, Tsuchimochi S, Taguchi A, Miyamoto Y, Sone K, Tsuruga T, Mori-Uchino M, Matsumoto Y, and Osuga Y
- Subjects
- BRCA1 Protein genetics, BRCA1 Protein metabolism, DNA, DNA Repair, Homologous Recombination, Transcription Factors metabolism, Mediator Complex Subunit 1 genetics, R-Loop Structures
- Abstract
Homologous recombination (HR) is a major repair pathway of DNA double-strand breaks and is closely related to carcinogenesis. HR deficiency has been established as a therapeutic target. The aim of this study was to elucidate the functions of a novel HR factor, Mediator complex subunit 1 (MED1), and its association with BRCA1. Formation of the MED1/BRCA1 complex was examined by immunoprecipitation and GST-pull down assays. The transcription cofactor role of BRCA1 was evaluated using luciferase assays. The roles of MED1 on DNA damage response and HR were analyzed by immunofluorescence and HR assays. R-loop accumulation was analyzed using immunofluorescence. R-loop-induced DNA damage was analyzed by comet assays. Immunoprecipitation and GST-pull down assays demonstrated that MED1 is a novel binding partner of BRCA1 and binds to the BRCT domain. Luciferase assays showed that MED1 potentiated the transcription ability of BRCT by two-fold. In MED1-depleted cells, recruitment of HR genes, such as RPA and γH2AX, to DNA damage sites was severely impaired. HR assays showed that MED1 knockdown significantly decreased HR activity. R-loop nuclear accumulation and R-loop-induced comet tails were observed in MED1-depleted cells. We conclude that the transcription factor MED1 contributes to the regulation of the HR pathway and R-loop processing., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
17. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study.
- Author
-
Ishizaka A, Taguchi A, Tsuruga T, Maruyama M, Kawata A, Miyamoto Y, Tanikawa M, Ikemura M, Sone K, Mori M, Koga K, Ushiku T, Oda K, and Osuga Y
- Subjects
- Carcinoma, Ovarian Epithelial, Female, Humans, Retrospective Studies, Carcinoma, Endometrioid complications, Carcinoma, Endometrioid diagnosis, Carcinoma, Endometrioid epidemiology, Endometrial Neoplasms complications, Endometrial Neoplasms epidemiology, Endometrial Neoplasms pathology, Endometriosis complications, Endometriosis pathology, Ovarian Neoplasms complications, Ovarian Neoplasms diagnosis, Ovarian Neoplasms epidemiology
- Abstract
Background: Endometriosis is assumed to be involved in ovarian cancer development, which is called endometriosis-associated ovarian cancer (EAOC). Uterine endometrial cells may be the cell of origin of EAOC. Accumulated carcinogenic changes in the uterine endometrial cells may increase the risk of developing EAOC. To further understand the pathogenesis of EAOCs, we focused on the clinicopathological characteristics of EAOCs in endometrial cancer patients with concomitant endometriosis., Methods: We retrospectively reviewed 376 patients who were surgically treated for stage I-III endometrial cancer. Clinicopathological characteristics were compared between patients with and without endometriosis. Furthermore, the incidence of simultaneous endometrial and ovarian cancer (SEOC) and the histological characteristics of SEOC were compared between the two groups., Results: Among 376 patients with endometrial cancer, 51 had concomitant endometriosis. Patients with endometriosis were significantly younger and more frequently had endometrioid G1/G2 tumors than those without endometriosis. The incidence of SEOCs was significantly higher in endometrial cancer patients with endometriosis than those without it (p < 0.0001); notably, 12 of 51 endometrial cancer patients with endometriosis (24%) had SEOCs. All of the ovarian cancers in endometrial cancer patients with endometriosis were endometrioid carcinomas. Moreover, even in those without endometriosis, endometrioid carcinoma was the most common histological type of SEOC., Conclusion: We revealed that endometrial cancer patients with endometriosis had a high probability of SEOC and that endometrioid carcinoma was the most common histological subtype of SEOC regardless of the presence of endometriosis. For patients with endometrial cancer and endometriosis, careful examination of ovarian endometriotic lesions may be important to detect EAOCs., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
18. Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.
- Author
-
Yoshimoto D, Taguchi A, Tanikawa M, Sone K, Shimoi T, Tsuruga T, Oda K, and Osuga Y
- Subjects
- Biomarkers, Tumor genetics, Chemotherapy, Adjuvant, Disease Progression, Female, Humans, Liver Neoplasms drug therapy, Liver Neoplasms genetics, Liver Neoplasms secondary, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological therapeutic use, B7-H1 Antigen genetics, Nivolumab administration & dosage, Nivolumab therapeutic use, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms genetics, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery
- Abstract
Patients with cervical cancer benefiting from immune checkpoint inhibitors (ICIs) are limited. Recently, PD-L1 amplification has been attracted attention as a reliable marker of ICIs. A 47-year-old woman with stage IIB cervical cancer experienced disease progression during postoperative adjuvant chemotherapy. Cancer genomic profiling revealed that the tumor was microsatellite stable with PD-L1 amplification, therefore, nivolumab was administered by enrolling in the BELIEVE trial. Despite nivolumab treatment, remarkable disease progression was observed. At the beginning of nivolumab treatment, the patient already had multiple liver metastases with severe systemic inflammation as indicated by a high neutrophil-to-lymphocyte ratio (NLR), both of which are negative predictive markers for ICI. Despite the presence of PD-L1 amplification, nivolumab was ineffective in cancer progression, which may be attributable to the presence of liver metastasis and high NLR. ICI is recommended to be administered at an early stage of cancer treatment to enhance its effectiveness., (© 2022 Japan Society of Obstetrics and Gynecology.)
- Published
- 2022
- Full Text
- View/download PDF
19. Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer.
- Author
-
Inoue F, Sone K, Toyohara Y, Tanimoto S, Takahashi Y, Kusakabe M, Kukita A, Honjoh H, Nishijima A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Uchino MM, Tsuruga T, Wada-Hiraike O, Oda K, and Osuga Y
- Subjects
- Apoptosis, Arginine metabolism, CARD Signaling Adaptor Proteins, Female, Guanylate Cyclase, Humans, Intracellular Signaling Peptides and Proteins, Methylation, Protein-Arginine N-Methyltransferases genetics, Protein-Arginine N-Methyltransferases metabolism, Endometrial Neoplasms drug therapy, Endometrial Neoplasms genetics, Histones metabolism
- Abstract
Histone modification is the key epigenetic mechanism that regulates gene expression. Coactivator-associated arginine methyltransferase 1 (CARM1) is an arginine methyltransferase that catalyzes dimethylation of histone H3 (H3R17) at arginine 17. Lately, it has been suggested that CARM1 is associated with human carcinogenesis, and the CARM1-selective inhibitor, TP-064, has been shown to be a potential therapeutic agent for multiple myeloma. However, the physiological significance of CARM1 in endometrial cancer remains unclear. Therefore, we aimed to explore the role of CARM1 and the effect of TP-064 in endometrial cancer. To this end, we analyzed CARM1 expression in endometrial cancer using quantitative real-time polymerase chain reaction and examined the antitumor mechanism with CARM1 knockdown endometrial cancer cells. Moreover, we evaluated the therapeutic capability of TP-064 in endometrial cancer cells. CARM1 was remarkably overexpressed in 52 endometrial cancer tissues compared to normal endometrial tissues. The growth of CARM1 knockdown endometrial cancer cells was suppressed and CARM1 knockdown induced apoptosis. TP-064 also inhibited endometrial cancer cell growth and declined the number of endometrial cancer cell colonies. These data suggest that CARM1 may be a powerful therapeutic target for endometrial cancer., Competing Interests: Declaration of competing interest K. Oda has research grants from Daiichi-Sankyo Co., Ltd. and Astrazeneca plc and lecture fees from Chugai Pharmaceutical Co., Ltd. and Astrazeneca plc. The other authors have no competing interests to disclose., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.
- Author
-
Taguchi A, Rokutan H, Oda K, Tanikawa M, Tanimoto S, Sone K, Mori M, Tsuruga T, Kohsaka S, Tatsuno K, Shinozaki-Ushiku A, Miyagawa K, Mano H, Aburatani H, Ushiku T, and Osuga Y
- Subjects
- Adult, Female, Humans, Proto-Oncogene Proteins p21(ras) genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Peritoneal Neoplasms genetics, Peritoneal Neoplasms pathology, Pseudomyxoma Peritonei genetics, Pseudomyxoma Peritonei pathology, Teratoma genetics, Teratoma pathology
- Abstract
Background: Pseudomyxoma peritonei is a rare disease condition mainly caused by primary mucinous tumors from the appendix and rarely from the ovary, such as when mucinous ovarian tumors arise from within a teratoma. Molecular analyses of pseudomyxoma from the appendix showed that KRAS and GNAS pathogenic variants are common genetic features of pseudomyxoma peritonei. However, the origin of the tumors is difficult to be identified via genetic variants alone. This study presents a case of pseudomyxoma peritonei of ovarian origin, which was diagnosed by comprehensive genomic profiling with ploidy analysis in a series of primary, recurrent, and autopsy tumor specimens., Case Presentation: A 40-year-old woman was diagnosed with Stage IC2 mucinous ovarian tumor of borderline malignancy with mature cystic teratoma, upon clinical pathology. Immunohistochemical analysis suggested that the mucinous tumor was derived from the intestinal component of an ovarian teratoma. Three years later, intraperitoneal recurrence was detected, which subsequently progressed to pseudomyxoma peritonei. Genomic analysis detected KRAS (G12D), GNAS (R201C), and FBXW7 (R367*) variants in the primary tumor. In addition, the tumor showed aneuploidy with loss of heterozygosity (LOH) in all its chromosomes, which suggested that the primary ovarian tumor was derived from germ cells. Existence of one Barr body suggested the existence of uniparental disomy of the tumors throughout the genome, instead of a haploid genotype. All three pathogenic variants remained positive in the initial recurrent tumor, as well as in the paired DNA from the whole blood in pseudomyxoma peritonei. The pathogenic variant of KRAS (G12D) was also identified in the autopsy specimen of the appendix by droplet digital polymerase chain reaction., Conclusions: This study pathologically and genetically confirmed that the primary ovarian borderline tumor was derived from the intestinal component of an ovarian teratoma, and that the subsequent pseudomyxoma peritonei progressed from the primary ovarian tumor. Integrative genomic analysis was useful to identify cellular origin of tumors, as well as to precisely interpret the process of disease progression., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
21. Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin.
- Author
-
Tojima Y, Taguchi A, Mori M, Nara K, Miyamoto Y, Tanikawa M, Sone K, Tsuruga T, Yamamoto T, Oda K, Suzuki H, and Osuga Y
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin adverse effects, Female, Filgrastim, Granulocyte Colony-Stimulating Factor adverse effects, Granulocyte Colony-Stimulating Factor therapeutic use, Humans, Polyethylene Glycols, Retrospective Studies, Cisplatin adverse effects, Endometrial Neoplasms drug therapy
- Abstract
Objective: Although the incidence of febrile neutropenia (FN) is relatively higher for doxorubicin and cisplatin combination regimen than for other regimens in endometrial cancer, evidence regarding the efficacy of pegfilgrastim in this regimen is lacking., Materials and Methods: We retrospectively reviewed the data of 58 patients with endometrial cancer who were treated with doxorubicin plus cisplatin. The patients were divided into primary prophylaxis and non-prophylaxis groups. We compared the incidence of FN and neutropenia as well as the chemotherapy relative dose intensity (RDI) and usage of antibiotics between the groups., Results: The rates of FN (8.0% vs. 34.8%) and grade 4 neutropenia (12.0% vs. 87.0%) were significantly lower in the primary prophylaxis group. Although there was no difference in the RDI between the groups, the primary prophylaxis group had a lower rate of antibiotic prescriptions., Conclusion: Prophylaxis with pegfilgrastim efficiently prevented FN in patients treated with doxorubicin and cisplatin., Competing Interests: Declaration of competing interest The authors have no conflicts of interest relevant to this article., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
22. Transiently elevated D-dimer levels post-concentrated ascites reinfusion therapy cannot be used to predict deep vein thrombosis-pulmonary embolism.
- Author
-
Sone K, Taguchi A, Kawata A, Eguchi S, Miyamoto Y, Tanikawa M, Uchino-Mori M, Iriyama T, Tsuruga T, and Osuga Y
- Subjects
- Ascites diagnosis, Ascites therapy, Fibrin Fibrinogen Degradation Products, Humans, Retrospective Studies, Pulmonary Embolism diagnosis, Venous Thrombosis diagnosis, Venous Thrombosis therapy
- Abstract
Aim: Cell-free and concentrated ascites reinfusion therapy (CART) is useful for treating malignant ascites. We have previously experienced cases with no DVT-PE despite a marked elevation in D-dimer post-CART. In this study, we assessed the changes in the D-dimer levels in patients who received CART and investigated the association between elevated D-dimer levels and occurrence of DVT-PE., Methods: We performed an observational retrospective analysis of patients with gynecological malignancies treated with CART between March 2018 and April 2021. The selected patients had their D-dimer levels measured before and post-CART. The presence or absence of clinical DVT-PE findings was then examined, and contrast-enhanced computed tomography was performed using a DVT protocol in some cases., Results: Eleven patients received 17 CART procedures in this study. Patients of 16 procedures (94.1%) showed a significant elevation in D-dimer levels on day 1 post-CART. Changes in D-dimer levels were monitored in these patients of 16 procedures. In all 16 cases, the D-dimer levels decreased after day 2 post-CART. Only one patient, who presented with respiratory failure, out of the patients of 16 procedures (6.2%) with elevated D-dimer levels on day 1 had PE., Conclusions: D-dimer elevation after CART is likely to be transient and a false-positive. None of the patients in this study had PE if they were asymptomatic after CART, there is no need to strongly suspect PE only by D-dimer elevation. In conclusion, D-dimer measurement immediately post-CART is not helpful in predicting the diagnosis of DVT-PE., (© 2022 Japan Society of Obstetrics and Gynecology.)
- Published
- 2022
- Full Text
- View/download PDF
23. Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report.
- Author
-
Sone K, Kukita A, Masui Y, Yamada D, Shinozaki-Ushiku A, Kawata A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Mori-Uchino M, Tsuruga T, and Osuga Y
- Abstract
In 5% of female patients with malignant melanoma (MM), MM develops from the genital tract. MM of the cervix is particularly rare. In the present case report, a 73-year-old woman with stage ⅢC cervical MM underwent modified radical hysterectomy, bilateral salpingo-oophorectomy and pelvic lymph node dissection. A total of 4 months after surgery, multiple metastases were found in the brain, lung, liver, lymph nodes and bone. The patient underwent γ-knife surgery of the brain and received treatment with anti PD-1 antibodies (nivolumab) and anti-CTLA4 antibodies (ipilimumab); however, they were ineffective and the patient subsequently died. To the best of our knowledge, this is the first report of treatment using two types of immune checkpoint inhibitors administered to a patient with cervical MM. Taken together with previous reports, this case suggests that immune checkpoint inhibitors may be less effective in cervical MM than in cutaneous MM; however, the number of cases is small. Further development of biomarkers to stratify efficacy is required., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Sone et al.)
- Published
- 2022
- Full Text
- View/download PDF
24. Prognosis of high-risk human papillomavirus-related cervical lesions: A hidden Markov model analysis of a single-center cohort in Japan.
- Author
-
Ikesu R, Taguchi A, Hara K, Kawana K, Tsuruga T, Tomio J, and Osuga Y
- Subjects
- Female, Genotype, Humans, Japan epidemiology, Papillomaviridae genetics, Prognosis, Retrospective Studies, Alphapapillomavirus genetics, Papillomavirus Infections complications, Papillomavirus Infections diagnosis, Papillomavirus Infections pathology, Uterine Cervical Neoplasms pathology
- Abstract
Introduction: Previous studies have shown that individuals with human papillomavirus (HPV)-related cervical lesions have different prognoses according to the HPV genotype. However, these studies failed to account for possible diagnostic misclassification. In this retrospective cohort study, we aimed to clarify the natural course of cervical lesions according to HPV genotype to account for any diagnostic misclassification., Materials and Methods: Our cohort included 729 patients classified as having cervical intraepithelial neoplasia (CIN). HPV was genotyped in all patients, who were followed up or treated for cervical lesions at the University of Tokyo Hospital from October 1, 2008 to March 31, 2015. Hidden Markov models were applied to estimate the diagnostic misclassification probabilities of the current diagnostic practice (histology and cytology) and the transitions between true states. We then simulated two-year transition probabilities between true cervical states according to HPV genotype., Results: Compared with lesions in patients with other HPV genotypes, lesions in HPV 16-positive patients were estimated to be more likely to increase in severity (i.e., CIN3/cancer); over 2 years, 17.7% (95% confidence interval [CI], 9.3%-29.3%) and 27.8% (95% CI, 16.6%-43.5%) of those with HPV 16 progressed to CIN3/cancer from the true states of CIN1 and CIN2, respectively, whereas 55%-70% of CIN1/2 patients infected with HPV 52/58 remained in the CIN1/2 category. Misclassification was estimated to occur at a rate of 3%-38% in the current diagnostic practice., Conclusion: This study contributes robust evidence to current literature on cervical lesion prognosis according to HPV genotype and quantifies the diagnostic misclassification of true cervical lesions., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
25. A Microbiome-Derived Peptide Induces Apoptosis of Cells from Different Tissues.
- Author
-
Saiki H, Okano Y, Yasuma T, Toda M, Takeshita A, Abdel-Hamid AM, Fridman D'Alessandro V, Tsuruga T, D'Alessandro-Gabazza CN, Katayama K, Sugimoto M, Fujimoto H, Yamanaka K, Kobayashi T, Cann I, and Gabazza EC
- Subjects
- Caspase 3 metabolism, Cell Line, Tumor, Epithelial Cells drug effects, Epithelial Cells pathology, HaCaT Cells, Humans, Keratinocytes drug effects, Keratinocytes pathology, Mitochondrial Membranes drug effects, Mitochondrial Membranes metabolism, Podocytes drug effects, Podocytes pathology, Reactive Oxygen Species metabolism, Retina pathology, Transforming Growth Factor beta1 metabolism, Apoptosis drug effects, Microbiota drug effects, Organ Specificity drug effects, Peptides pharmacology
- Abstract
Apoptosis is a programmed cell death involved in embryogenesis and tissue homeostasis under physiological conditions. However, abnormalities in the process of apoptosis are implicated in the pathogenesis of various diseases. The human microbiota may release products that induce apoptosis of host cells. We recently identified a novel microbiome-derived peptide called corisin that worsens lung fibrosis by inducing apoptosis of lung epithelial cells. We hypothesized that corisin and a corisin-like peptide might also induce apoptosis of cells from different tissues. We cultured podocytes, renal tubular epithelial cells, keratinocytes, retinal and intestinal cells treated with corisin and evaluated apoptosis by flow cytometry and Western blotting. Although at different grades, flow cytometry analysis and Western blotting showed that corisin and a corisin-like peptide induced apoptosis of podocytes, keratinocytes, tubular epithelial cells, retinal, and intestinal cells. In addition, we found that corisin synergistically enhances the proapoptotic activity of transforming growth factor-β1 on podocytes. In conclusion, these results suggest that corisin and corisin-like peptides may play a role in the pathogenesis of disease in different organs by promoting apoptosis of parenchymal cells.
- Published
- 2021
- Full Text
- View/download PDF
26. A case of difficult-to-diagnose non-invasive papillary squamous cell carcinoma of the uterine cervix infected with human papilloma virus 6: A diagnostic pitfall.
- Author
-
Sone K, Inoue F, Taguchi A, Hinata M, Ikemura M, Miyamoto Y, Michihiro T, Ohno T, Iriyama T, Mori-Uchino M, Tsuruga T, Mishima M, and Osuga Y
- Abstract
We encountered HPV6-positive cervical papillary squamous cancer (PSCC) that was difficult to diagnose. The case was initially diagnosed and treated for condyloma. To the best of our knowledge, this is the first report of HPV6 infection in PSCC., Competing Interests: We have no conflicts of interest to declare regarding this case., (© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
27. History of whole pelvis plus para-aortic radiation is a risk factor associated with febrile neutropenia during chemotherapy for recurrent cervical cancer.
- Author
-
Nara K, Taguchi A, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Tsuruga T, Yamamoto T, Takenaka R, Takada T, Osuga Y, and Suzuki H
- Abstract
Background: Radiation-based therapy is widely used for advanced cervical cancer. Prior radiation-based therapy is a potential risk factor for febrile neutropenia (FN). However, the effect of irradiation field size on the incidence of FN during recurrent cervical cancer treatment is unclear. This study aimed to investigate the relationship between prior irradiation field size and FN development during recurrent chemotherapy., Methods: This retrospective, observational study included cervical cancer patients who received recurrent chemotherapy between November 2006 and June 2020. The patients were classified into two groups based on the area of irradiation fields. The first group included patients with a history of whole pelvis (WP) irradiation (WP group). The second group had patients who underwent WP plus para-aortic lymph node (PAN) irradiation (WP + PAN group). The incidences of hematological toxicities and FN during the recurrent chemoradiotherapy were compared between the two groups., Results: The FN incidence was significantly higher in the WP + PAN group than in the WP group (32.1% vs. 0%, P < 0.001). The incidence of Grade 4 neutropenia was not significantly different between the WP + PAN and WP groups. The nadir absolute neutrophil counts were significantly lower and the dose reduction or discontinuation rate of chemotherapy was significantly higher in the WP + PAN group than in the WP group., Conclusion: History of WP plus PAN radiation is a risk factor for developing FN during recurrent cervical cancer chemotherapy., (© 2021. Japan Society of Clinical Oncology.)
- Published
- 2021
- Full Text
- View/download PDF
28. Application of artificial intelligence in gynecologic malignancies: A review.
- Author
-
Sone K, Toyohara Y, Taguchi A, Miyamoto Y, Tanikawa M, Uchino-Mori M, Iriyama T, Tsuruga T, and Osuga Y
- Subjects
- Female, Humans, Machine Learning, Magnetic Resonance Imaging, Artificial Intelligence, Genital Neoplasms, Female diagnosis
- Abstract
With the development of machine learning and deep learning models, artificial intelligence is now being applied to the field of medicine. In oncology, the use of artificial intelligence for the diagnostic evaluation of medical images such as radiographic images, omics analysis using genome data, and clinical information has been increasing in recent years. There have been increasing numbers of reports on the use of artificial intelligence in the field of gynecologic malignancies, and we introduce and review these studies. For cervical and endometrial cancers, the evaluation of medical images, such as colposcopy, hysteroscopy, and magnetic resonance images, using artificial intelligence is frequently reported. In ovarian cancer, many reports combine the assessment of medical images with the multi-omics analysis of clinical and genomic data using artificial intelligence. However, few study results can be implemented in clinical practice, and further research is needed in the future., (© 2021 Japan Society of Obstetrics and Gynecology.)
- Published
- 2021
- Full Text
- View/download PDF
29. CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report.
- Author
-
Suzuki S, Kurokawa R, Tsuruga T, Mori-Uchino M, Nishida H, Kato T, Abe H, Ushiku T, Amemiya S, Katayama A, and Abe O
- Abstract
Endometrial stromal sarcoma is a rare uterine mesenchymal neoplasm, and extrauterine endometrial stromal sarcoma is even rarer, with a limited number of case reports. In the present report, we present a case of low-grade extrauterine endometrial stromal sarcoma originating from the mesentery in a 49-year-old woman, without endometrial stromal sarcoma in the uterus or evidence of endometriosis. The tumor was diagnosed using recombination of the JAZF1 gene by fluorescence in situ hybridization. Computed tomography, magnetic resonance imaging, and 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed a 13 cm, primarily polycystic, mass containing a contrast-enhancing solid component with restricted diffusion and mild 18F-fluorodeoxyglucose uptake. A large cystic component may be a characteristic feature of extrauterine endometrial stromal sarcoma, given the low pressure from the surrounding tissues., (© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington.)
- Published
- 2021
- Full Text
- View/download PDF
30. A low preoperative albumin-to-globulin ratio is a negative prognostic factor in patients with surgically treated cervical cancer.
- Author
-
Kawata A, Taguchi A, Baba S, Miyamoto Y, Tanikawa M, Sone K, Tsuruga T, Mori M, Oda K, Kawana K, Osuga Y, and Fujii T
- Abstract
Background: The albumin-to-globulin ratio reflects both the nutrition and inflammation and predicts prognosis in patients with various malignancies. However, in cervical cancer patients who undergo surgery, its significance has yet to be established., Methods: A total of 247 cervical cancer patients who received surgical treatment at our institution between 2005 and 2017 were enrolled in this study. Preoperative data, such as the levels of serum albumin and serum globulin as well as the albumin-to-globulin ratio along with the other clinicopathological characteristics were retrospectively assessed, and their association with the overall survival was analyzed., Results: Overall, 49 cases of recurrence and 26 deaths were observed during the median follow-up time of 58.6 months. A low albumin-to-globulin ratio (< 1.345) as well as low albumin (< 3.25 g/dL) and high globulin levels (≥ 3.25 g/dL) were significantly associated with poor prognosis. According to the multivariate analysis, a low albumin-to-globulin ratio was an independent prognostic factor for overall survival (HR = 2.59, 95% CI 1.12-5.96, P = 0.026); however, low albumin or high globulin levels was not associated with the overall survival. Among the clinicopathological characteristics, older age, diabetes mellitus, hypertension, larger tumor size, and parametrial invasion were associated with a low albumin-to-globulin ratio., Conclusion: A low albumin-to-globulin ratio was associated with a poor prognosis in patients with surgically treated invasive cervical cancer. Therefore, the albumin-to-globulin ratio may serve as a prognostic marker, which predicts a worse prognosis.
- Published
- 2021
- Full Text
- View/download PDF
31. A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing Lactobacillus , GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2).
- Author
-
Ikeda Y, Adachi K, Tomio K, Eguchi-Kojima S, Tsuruga T, Uchino-Mori M, Taguchi A, Komatsu A, Nagamatsu T, Oda K, Kawana-Tachikawa A, Uemura Y, Igimi S, Osuga Y, Fujii T, and Kawana K
- Abstract
Cervical intraepithelial neoplasia (CIN), a precursor lesion to cervical cancer, is caused by high-risk human papillomavirus (HPV); high-grade CIN lesions (CIN2-3) are precancerous and require treatment. No globally approved therapy is available for CIN2-3 treatment. This study is a placebo-controlled randomized clinical trial of GLBL101c treatment for CIN2 in 40 patients with HPV16-positive CIN2 who were 1:1 randomized to receive GLBL101c (1 g/daily) or placebo for 5 days at 1, 2, 4, and 8 weeks. No differences were noted between the GLBL101c and placebo groups for patient background and adverse events. Moreover, no statistically significant difference was noted between the two groups at the primary endpoint, pathological regression after 16 weeks of the first oral dose; however, only in the GLBL101c group, two patients had complete regression (CR; regression to normal within 16 weeks). IFNγ production was significantly correlated with the number of spots identified by the interferon gamma enzyme-linked immunospot (IFNγ-ELISPOT) assay using cervical lymphocytes (CxLs) or peripheral blood mononuclear cells. In the two cases of CR, E7-specific Th1 immune responses were observed at week 16. Therefore, we concluded as a novel Lactobacillus -based vaccine with stronger immunogenicity than GLBL101c should be developed.
- Published
- 2021
- Full Text
- View/download PDF
32. Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy.
- Author
-
Takahashi Y, Sone K, Noda K, Yoshida K, Toyohara Y, Kato K, Inoue F, Kukita A, Taguchi A, Nishida H, Miyamoto Y, Tanikawa M, Tsuruga T, Iriyama T, Nagasaka K, Matsumoto Y, Hirota Y, Hiraike-Wada O, Oda K, Maruyama M, Osuga Y, and Fujii T
- Subjects
- Data Accuracy, Female, Humans, Sensitivity and Specificity, Deep Learning, Early Detection of Cancer methods, Electronic Data Processing methods, Endometrial Hyperplasia diagnosis, Endometrial Neoplasms diagnosis, Hysteroscopy methods, Leiomyoma diagnosis, Polyps diagnosis, Uterine Neoplasms diagnosis
- Abstract
Endometrial cancer is a ubiquitous gynecological disease with increasing global incidence. Therefore, despite the lack of an established screening technique to date, early diagnosis of endometrial cancer assumes critical importance. This paper presents an artificial-intelligence-based system to detect the regions affected by endometrial cancer automatically from hysteroscopic images. In this study, 177 patients (60 with normal endometrium, 21 with uterine myoma, 60 with endometrial polyp, 15 with atypical endometrial hyperplasia, and 21 with endometrial cancer) with a history of hysteroscopy were recruited. Machine-learning techniques based on three popular deep neural network models were employed, and a continuity-analysis method was developed to enhance the accuracy of cancer diagnosis. Finally, we investigated if the accuracy could be improved by combining all the trained models. The results reveal that the diagnosis accuracy was approximately 80% (78.91-80.93%) when using the standard method, and it increased to 89% (83.94-89.13%) and exceeded 90% (i.e., 90.29%) when employing the proposed continuity analysis and combining the three neural networks, respectively. The corresponding sensitivity and specificity equaled 91.66% and 89.36%, respectively. These findings demonstrate the proposed method to be sufficient to facilitate timely diagnosis of endometrial cancer in the near future., Competing Interests: Kenbun Sone has a joint research agreement with Predicthy LLC. Katsuhiko Noda and Kaname Yoshida are members of Predicthy LLC. The other authors have no competing interests to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2021
- Full Text
- View/download PDF
33. Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications.
- Author
-
Inoue F, Sone K, Toyohara Y, Takahashi Y, Kukita A, Hara A, Taguchi A, Tanikawa M, Tsuruga T, and Osuga Y
- Subjects
- Acetylation, Chromatin Immunoprecipitation Sequencing, DNA Methylation drug effects, Disease Progression, Endometrial Neoplasms drug therapy, Endometrial Neoplasms genetics, Epigenesis, Genetic drug effects, Female, Gene Expression Regulation drug effects, Gene Expression Regulation genetics, Humans, Neoplasm Recurrence, Local drug therapy, RNA, Untranslated genetics, Endometrial Neoplasms metabolism, Histones metabolism, Methylation drug effects, Neoplasm Recurrence, Local metabolism, RNA, Untranslated metabolism
- Abstract
Endometrial cancer is one of the most frequently diagnosed gynecological malignancies worldwide. However, its prognosis in advanced stages is poor, and there are only few available treatment options when it recurs. Epigenetic changes in gene function, such as DNA methylation, histone modification, and non-coding RNA, have been studied for the last two decades. Epigenetic dysregulation is often reported in the development and progression of various cancers. Recently, epigenetic changes in endometrial cancer have also been discussed. In this review, we give the main points of the role of DNA methylation and histone modification in endometrial cancer, the diagnostic tools to determine these modifications, and inhibitors targeting epigenetic regulators that are currently in preclinical studies and clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
34. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
- Author
-
Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, and Fujii T
- Subjects
- Apoptosis, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Cell Survival, DNA Methylation, Disease Progression, Female, Histones metabolism, Humans, Inhibitory Concentration 50, Lysine chemistry, Prognosis, Quinazolines pharmacology, RNA, Small Interfering metabolism, Transfection, Up-Regulation, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Histone-Lysine N-Methyltransferase genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms metabolism
- Abstract
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
- Published
- 2020
- Full Text
- View/download PDF
35. Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer.
- Author
-
Toyohara Y, Sone K, Nishida H, Taguchi A, Miyamoto Y, Tanikawa M, Mori M, Tsuruga T, Matsumoto Y, Oda K, Osuga Y, and Fujii T
- Subjects
- Carboplatin adverse effects, Desensitization, Immunologic, Female, Humans, Neoplasm Recurrence, Local, Retrospective Studies, Antineoplastic Agents adverse effects, Drug Hypersensitivity drug therapy, Drug Hypersensitivity therapy
- Abstract
Aim: Carboplatin is a key drug for gynecologic cancers. However, hypersensitivity reactions (HSR) are major adverse effects that might necessitate carboplatin discontinuation. Desensitization is an effective method in patients who developed initial HSR and further required carboplatin treatment. Here, we aimed to evaluate our experience with the use of the carboplatin desensitization protocol in five patients at the University of Tokyo Hospital., Methods: We established a four-step, 5-h desensitization protocol for our hospital. Observational and retrospective analyses were performed. Additionally, we have shared the patients' clinical information with the emergency department to ensure the safety of this protocol., Results: Five patients with recurrent gynecological cancer were treated using this protocol. Four of the five patients were treated effectively and 28 of 29 desensitization protocols were completed successfully. In one patient, we switched to olaparib successfully after two courses of our protocol. One patient who developed grade 4 HSR during initial carboplatin administration developed grade 2 HSR and we discontinued the protocol., Conclusion: The carboplatin desensitization protocol is very efficient. The outcome of our protocol was on a par with other protocols. To the best of our knowledge, this is the first study to indicate that switching to olaparib can be considered a suitable option in patients who develop HSR to carboplatin., (© 2020 Japan Society of Obstetrics and Gynecology.)
- Published
- 2020
- Full Text
- View/download PDF
36. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
- Author
-
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Kawata A, Honjoh H, Kawata Y, Kashiyama T, Sato M, Taguchi A, Miyamoto Y, Tanikawa M, Tsuruga T, Nagasaka K, Wada-Hiraike O, Osuga Y, and Fujii T
- Abstract
Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether SMYD2 could serve a therapeutic role in ovarian clear cell carcinoma (OCCC). Reverse transcription-quantitative PCR was used to examine SMYD2 expression in 23 clinical OCCC specimens. Moreover, OCCC cell proliferation and cell cycle progression were also examined following small interfering RNA-mediated SMYD2 silencing or treatment with a selective SMYD2 inhibitor. SMYD2 was significantly upregulated in clinical OCCC specimens, compared with normal ovarian tissue. In addition, SMYD2 knockdown decreased cell viability as determined via a Cell Counting Kit-8 assay. Moreover, the proportion of cells in the sub-G
1 phase increased following SMYD2 knockdown, suggesting increased apoptosis. Treatment with the SMYD2 inhibitor LLY-507 suppressed OCCC cell viability. These results suggested that SMYD2 could promote OCCC viability, and that SMYD2 inhibition induced apoptosis in these cells. Thus, SMYD2 inhibitors may represent a promising molecular targeted approach for OCCC treatment., (Copyright: © Kojima et al.)- Published
- 2020
- Full Text
- View/download PDF
37. [Clinical Significance of the Curative Effect after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer-Correlation to Prognosis].
- Author
-
Haku E, Kojima Y, Sakamaki K, Kitajima M, Takishita M, Sakamoto N, Tazou M, Nakano M, Kuroda T, Yoshie R, Tsuruga T, Shimo A, Shimo A, Motoyoshi A, Kawamoto H, Fukuda M, and Tsugawa K
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease-Free Survival, Humans, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Prognosis, Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms drug therapy
- Abstract
We investigated factors related to the recurrence and prognosis of patients with triple-negative breast cancer (TNBC)after neoadjuvant chemotherapy(NAC). Of the 545 patients who underwent surgery after NAC between January 2013 and December 2016, 131 patients had TNBC. An analysis of each TNBC case indicated that the presence or absence of clinical lymph node metastasis(cN)before treatment might be a predictive factor of prognosis. There were 57(43.5%)pathological complete response(pCR)(ypT0 or ypTis/N0)cases after NAC. Overall survival(OS)and disease free survival(DFS) were significantly better in pCR cases than in non-pCR cases. However, recurrence was observed in 8 of 57(14%)pCR cases and 29 of 74(39%)non-pCR cases. The factors defining DFS from the univariate analysis of the non-pCR group were cN, ypT, ypN, and vascular invasion. The multivariate analysis of these factors suggested that residual cN and vascular invasion might be independent factors predicting DFS. Residual vascular invasion was found to predict OS, and was considered to be a poor prognostic factor.
- Published
- 2020
38. Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report.
- Author
-
Sone K, Eguchi S, Asada K, Inoue F, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Matsumoto Y, Hiraike-Wada O, Oda K, Osuga Y, and Fujii T
- Abstract
A diagnostic biopsy for endometrial cancer is performed via dilation and curettage (D&C). However, D&C may miss endometrial cancer lesions due to of its 'blind' approach. Hysteroscopy is a useful method that can be used to detect endometrial cancer lesions. In addition, office hysteroscopy is easy to be scheduled and does not require anesthesia. The patient was a 40-year-old woman with suspected endometrial cancer; however, it could not be diagnosed by D&C and biopsy using hysteroscopy during hospitalization. Office hysteroscopy during the proliferative phase indicated that the suspicious endometrial cancerous lesion was minimal at the isthmus of the uterus with atypical vessels and a white spot, for which biopsy was performed. Pathological diagnosis was endometrioid carcinoma with squamous differentiation, G1. Therefore, total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy were performed. In this case, it was difficult to detect minimal lesion in the secretory phase because the endometrial thickness hid the endometrial cancer. It is easy to perform office hysteroscopy in the proliferative phase. This case indicated that office hysteroscopy is a useful method to diagnose and perform biopsy for minimal lesions., (Copyright: © Sone et al.)
- Published
- 2020
- Full Text
- View/download PDF
39. Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma: Evaluation of tumour markers and "mille-feuille sign" on computed tomography/magnetic resonance imaging.
- Author
-
Kurokawa R, Nakai Y, Gonoi W, Mori H, Tsuruga T, Makise N, Ushiku T, and Abe O
- Subjects
- Adult, Aged, Biomarkers, Tumor blood, CA-125 Antigen blood, Diagnosis, Differential, Female, Humans, Middle Aged, Ovarian Neoplasms pathology, Ovarian Neoplasms secondary, Ovary diagnostic imaging, Ovary pathology, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Colorectal Neoplasms pathology, Magnetic Resonance Imaging methods, Multimodal Imaging methods, Ovarian Neoplasms diagnostic imaging, Tomography, X-Ray Computed methods
- Abstract
Purpose: The purpose of this retrospective study was to evaluate the usefulness of serum tumour markers and morphological characteristics in CT/MRI to differentiate between ovarian metastases from colorectal carcinomas (OMCRC) and primary ovarian carcinomas (POC)., Method: Preoperative radiological images of 41 OMCRCs from 27 patients (mean age ± SD: 52.2 ± 10.7 years) and 46 POCs from 36 patients (52.1 ± 12.7 years) were included. Three blinded gynecological radiologists classified tumour morphology into 'mille-feuille sign', 'solid and cystic', 'multicystic without nodules', and 'multicystic with nodules' groups and analysed using Fisher's exact test. Serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and carbohydrate antigen 19-9 levels were compared by Wilcoxon rank-sum test., Results: 'Mille-feuille sign' indicated OMCRC (OMCRC: 8/41, POC: 1/46, specificity = 0.98, p = 0.011) and had excellent interobserver agreement (Fleiss's kappa value = 0.96). 'Solid and cystic' indicated POC (18/41 vs 41/45, p < 0.001) and 'multicystic without nodules' indicated OMCRC (8/41 vs 2/46, p = 0.041). There was no significant difference in 'multicystic with nodules'. CA125 levels were higher in POCs (292.5 U/mL vs. 41.0 U/mL, p = 0.003). CEA levels were higher in OMCRCs (24.5 ng/mL vs 2 ng/mL, p < 0.001). CEA (< 6.3 ng/mL) AND (CA125 (≥87.0 U/mL) OR 'solid and cystic') indicated POC with high accuracy (3/41 vs 44/46, accuracy = 0.94, p < 0.001)., Conclusions: Our new method with morphological classification and tumour markers were useful for differentiating the two tumours. In particular, the 'mille-feuille sign' frequently indicated OMCRC with high specificity and excellent interobserver agreement., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest directly relevant to the content of this article., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. Production of an anti-angiogenic factor sFLT1 is suppressed via promoter hypermethylation of FLT1 gene in choriocarcinoma cells.
- Author
-
Sasagawa T, Jinno-Oue A, Nagamatsu T, Morita K, Tsuruga T, Mori-Uchino M, Fujii T, and Shibuya M
- Subjects
- Animals, Cell Line, Tumor, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Choriocarcinoma pathology, CpG Islands, Disease Models, Animal, Female, Humans, Hypoxia genetics, Hypoxia metabolism, Mice, Neovascularization, Pathologic genetics, Neovascularization, Pathologic metabolism, Protein Isoforms, RNA Splicing, RNA, Messenger genetics, RNA, Messenger metabolism, Vascular Endothelial Growth Factor A genetics, Xenograft Model Antitumor Assays, Choriocarcinoma genetics, Choriocarcinoma metabolism, DNA Methylation, Gene Expression Regulation, Neoplastic, Promoter Regions, Genetic, Vascular Endothelial Growth Factor Receptor-1 biosynthesis, Vascular Endothelial Growth Factor Receptor-1 genetics
- Abstract
Background: Soluble Fms-like tyrosine kinase-1 (sFLT1) as an anti-angiogenic factor is abundantly expressed in placental trophoblasts. Choriocarcinoma, a malignant tumor derived from trophoblasts, is known to be highly angiogenic and metastatic. However, the molecular mechanism underlying angiogenesis in choriocarcinoma pathogenesis remains unclear. We aimed to investigate the mRNA expression and DNA methylation status of the FLT1 gene in human choriocarcinoma cells and trophoblast cells., Methods: qRT-PCR, Western blotting and ELISA were conducted to evaluate the mRNA and protein expression levels of sFLT1. 5-aza-2'-deoxycytidine (5azadC) treatment and bisulfite sequencing were used to study the FLT1 gene promoter methylation. The effect of sFLT1 on choriocarcinoma growth and angiogenesis was evaluated in a xenograft mouse model., Results: Expression of the FLT1 gene was strongly suppressed in choriocarcinoma cell lines compared with that in the primary trophoblasts. Treatment of choriocarcinoma cell lines with 5azadC, a DNA methyltransferase inhibitor, markedly increased in mRNA expression of three FLT1 splice variants and secretion of sFLT1 proteins. Bisulfite sequencing revealed that the CpG hypermethylation was observed at the FLT1 promoter region in choriocarcinoma cell lines and a human primary choriocarcinoma tissue but not in human trophoblast cells. Interestingly, in 5azadC-treated choriocarcinoma cell lines, sFLT1 mRNA expression and sFLT1 production were further elevated by hypoxic stimulation. Finally, as expected, sFLT1-expressing choriocarcinoma cells implanted into nude mice showed significantly slower tumor growth and reduced microvessel formation compared with GFP-expressing control choriocarcinoma cells., Conclusions: Inhibition of sFLT1 production by FLT1 silencing occurs via the hypermethylation of its promoter in choriocarcinoma cells. The stable expression of sFLT1 in choriocarcinoma cells resulted in the suppression of tumor growth and tumor vascularization in vivo. We suggest that the FLT1 gene may be a cell-type-specific tumor suppressor in choriocarcinoma cells.
- Published
- 2020
- Full Text
- View/download PDF
41. ASK1 promotes uterine inflammation leading to pathological preterm birth.
- Author
-
Yoshikawa M, Iriyama T, Suzuki K, Sayama S, Tsuruga T, Kumasawa K, Nagamatsu T, Homma K, Naguro I, Osuga Y, Ichijo H, and Fujii T
- Subjects
- Animals, Apoptosis immunology, Cytokines metabolism, Disease Models, Animal, Female, Humans, Lipopolysaccharides administration & dosage, Lipopolysaccharides immunology, MAP Kinase Kinase Kinase 5 genetics, MAP Kinase Signaling System genetics, MAP Kinase Signaling System immunology, Mice, Mice, Knockout, Peritoneal Cavity pathology, Pregnancy, Premature Birth pathology, Uterus pathology, MAP Kinase Kinase Kinase 5 metabolism, Premature Birth immunology, Uterus immunology
- Abstract
It is widely accepted that enhanced uterine inflammation associated with microbial infection is a main causative factor for preterm birth. However, little is known about the molecular basis by which inflammation is associated with preterm birth. Here, we demonstrate that apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein 3-kinase family, facilitates inflammation-induced preterm birth and that inhibition of ASK1 activity is sufficient to suppress preterm birth. ASK1-deficient pregnant mice exhibited reduced incidence of lipopolysaccharide (LPS)-induced preterm birth. ASK1 was required for the induction of LPS-induced inflammatory responses related to preterm birth, including pro-inflammatory cytokine production in the uterus and peritoneal cavities. In addition, selective suppression of uterine ASK1 activity through a chemical genetic approach reduced the incidence of LPS-induced preterm birth. Moreover, translational studies with human choriodecidua demonstrated that ASK1 was required for LPS-induced activation of JNK and p38 and pro-inflammatory cytokine production. Our findings suggest that ASK1 activation is responsible for the induction of inflammation that leads to preterm birth and that the blockade of ASK1 signaling might be a promising therapeutic target for preventing preterm birth.
- Published
- 2020
- Full Text
- View/download PDF
42. Reconstructed uterine length is critical for the prevention of cervical stenosis following abdominal trachelectomy in cervical cancer patients.
- Author
-
Nakajima T, Kasuga A, Hara-Yamashita A, Ikeda Y, Asai-Sato M, Nakao T, Hayashi C, Takeya C, Adachi K, Tsuruga T, Matsumoto Y, Arimoto T, Nagamatsu T, Oda K, Komatsu A, Chishima F, Osuga Y, Fujii T, and Kawana K
- Subjects
- Adult, Constriction, Pathologic etiology, Female, Humans, Incidence, Japan epidemiology, Organ Sparing Treatments, Postoperative Complications epidemiology, Postoperative Complications etiology, Pregnancy, Pregnancy Rate, Trachelectomy methods, Postoperative Complications prevention & control, Trachelectomy adverse effects, Uterine Cervical Neoplasms surgery
- Abstract
Aim: Although the procedure of abdominal trachelectomy has been remarkably improved, preventing subsequent cervical stenosis remains challenging. In this study, we analyzed the clinicopathological risk factors for cervical stenosis to explore the appropriate surgical procedures for the prevention of cervical stenosis following trachelectomy., Methods: Thirty-two patients who underwent abdominal extended and radical trachelectomy were assessed retrospectively (median follow-up period = 33 months). To evaluate the risk factors, the clinicopathological factors were analyzed by univariate and multivariate analyses. The reconstructed uterine length (UtL), that is, the length between the vaginal end of the neo-cervix and the uterine fundus, was measured by transvaginal ultrasound after surgery. The cut-off value for the UtL was assessed by a receiver operating characteristic (ROC) curve analysis., Results: Cervical stenosis of any grade was observed in 12 patients (grade 1 = 9, grade 3b = 3). Among the various clinicopathological factors, the UtL and cervical length (CL) were significantly related to cervical stenosis following trachelectomy. The multivariate analysis revealed that the UtL, but not CL, is an independent risk factor for stenosis. The ROC curve analysis revealed that stenosis was significantly more likely to occur in patients with a UtL shorter than 53 mm (area under the ROC curve = 0.902). UtL in the patients who became pregnant was longer than that in the patients who did not. No evidence of recurrent cancer was observed during the follow-up period., Conclusion: Our proposed method may provide a functional reconstructed uterus with preserving fertility by remaining UtL more than 53 mm., (© 2020 Japan Society of Obstetrics and Gynecology.)
- Published
- 2020
- Full Text
- View/download PDF
43. Multistate Markov Model to Predict the Prognosis of High-Risk Human Papillomavirus-Related Cervical Lesions.
- Author
-
Taguchi A, Hara K, Tomio J, Kawana K, Tanaka T, Baba S, Kawata A, Eguchi S, Tsuruga T, Mori M, Adachi K, Nagamatsu T, Oda K, Yasugi T, Osuga Y, and Fujii T
- Abstract
Cervical intraepithelial neoplasia (CIN) has a natural history of bidirectional transition between different states. Therefore, conventional statistical models assuming a unidirectional disease progression may oversimplify CIN fate. We applied a continuous-time multistate Markov model to predict this CIN fate by addressing the probability of transitions between multiple states according to the genotypes of high-risk human papillomavirus (HPV). This retrospective cohort comprised 6022 observations in 737 patients (195 normal, 259 CIN1, and 283 CIN2 patients at the time of entry in the cohort). Patients were followed up or treated at the University of Tokyo Hospital between 2008 and 2015. Our model captured the prevalence trend satisfactory, particularly for up to two years. The estimated probabilities for 2-year transition to CIN3 or more were the highest in HPV 16-positive patients (13%, 30%, and 42% from normal, CIN1, and CIN2, respectively) compared with those in the other genotype-positive patients (3.1%-9.6%, 7.6%-16%, and 21%-32% from normal, CIN1, and CIN2, respectively). Approximately 40% of HPV 52- or 58-related CINs remained at CIN1 and CIN2. The Markov model highlights the differences in transition and progression patterns between high-risk HPV-related CINs. HPV genotype-based management may be desirable for patients with cervical lesions., Competing Interests: The authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
44. Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
- Author
-
Makii C, Ikeda Y, Oda K, Uehara Y, Nishijima A, Koso T, Kawata Y, Kashiyama T, Miyasaka A, Sone K, Tanikawa M, Tsuruga T, Mori-Uchino M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Kawana K, Hasegawa K, Fujiwara K, Aburatani H, Osuga Y, and Fujii T
- Subjects
- Adenine analogs & derivatives, Adenine pharmacology, Adenocarcinoma, Clear Cell, Animals, Antineoplastic Agents pharmacology, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases, DNA, Complementary metabolism, Female, Heterografts, Imidazolines pharmacology, Mice, Nude, Neoplasm Transplantation physiology, Ovarian Neoplasms metabolism, Piperazines pharmacology, Protein Kinase Inhibitors pharmacology, RNA, Messenger metabolism, RNA, Neoplasm metabolism, Random Allocation, Ovarian Neoplasms drug therapy, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-mdm2 antagonists & inhibitors
- Abstract
Introduction: PI3K pathway signaling has received attention as a molecular target in clear cell ovarian carcinoma (CCOC). MDM2 is one of the AKT effectors in the PI3K pathway, which binds to and degrades p53. In this study, we aimed to clarify the prognostic significance of PIK3CA and MDM2 expression, and potential therapeutic effect of a dual inhibition of the PI3K pathway and MDM2., Materials and Methods: cDNA expression was evaluated by using microarray data using 75 samples of CCOC. DS-7423 (dual inhibitor of pan-PI3K and mTOR) and RG7112 (MDM2 inhibitor) were used on CCOC cell lines to evaluate cell proliferation, expression level of MDM2 related proteins, and apoptosis by MTT assay, western blotting, and flow cytometry. DS-7423 (3 mg/kg) and/or RG7112 (50 mg/kg) were orally administrated every day for three weeks, and the anti-tumor effect was evaluated using tumor xenografts, along with immunohistochemistry., Results: Tumors with high expression of both PIK3CA and MDM2 showed significantly worse prognosis in expression array of 71 CCOCs (P = 0.013). Dual inhibition of the PI3K pathway by DS-7423 and MDM2 by RG7112 showed synergistic anti-proliferative effect in 4 CCOC cell lines without TP53 mutations. The combination therapy more robustly induced pro-apoptotic proteins (PUMA and cleaved PARP) with increase of sub G1 population and apoptotic cells, compared with either single agent alone. The combination therapy significantly reduced tumor volume in mice (P < 0.001 in OVISE, and P = 0.038 in RMG-I) without severe body weight loss. Immunohistochemistry from the xenograft tumors showed that the combination treatment significantly reduced vascularity and cell proliferation, with an increase of apoptotic cell death., Conclusion: A combination therapy targeting the PI3K pathway and MDM2 might be a promising therapeutic strategy in CCOC., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
45. Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma.
- Author
-
Aotsuka A, Matsumoto Y, Arimoto T, Kawata A, Ogishima J, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Kawana K, Osuga Y, and Fujii T
- Subjects
- Adult, Aged, Case-Control Studies, Cell Line, Tumor, Endometrial Neoplasms immunology, Female, Gene Expression Regulation, Neoplastic, Humans, Interleukin-17 metabolism, Intraepithelial Lymphocytes metabolism, Ovarian Neoplasms immunology, Phosphorylation, Prognosis, Th17 Cells metabolism, Up-Regulation, B7-H1 Antigen genetics, Endometrial Neoplasms genetics, Interleukin-16 metabolism, Interleukin-17 genetics, Ovarian Neoplasms genetics, STAT3 Transcription Factor metabolism
- Abstract
The programmed cell death 1/programmed cell death 1 ligand 1 pathway was successfully targeted in cancer immunotherapy. Elevated interleukin-17 (IL-17), which is known in autoimmune diseases, has recently been recognized in cancer patients. We investigated the role of IL-17 in the regulation of expression of programmed cell death 1 ligand 1 in ovarian cancer by evaluating changes in the number of IL-17-producing cluster of differentiation 4 helper T cells (Th17) and γδT cells (γδT17) in PBMC of 52 gynecological cancer patients (including 30 ovarian cancer patients) and 18 healthy controls. The occupancy ratio of Th17 and γδT17 was higher in ovarian cancer and endometrial cancer patients than in controls, determined by multi-color flow cytometry (Th17: P < 0.0001 and P = 0.0002, respectively; γδT17: P = 0.0020 and P = 0.0084, respectively). IL-17 mRNA level was elevated in PBMC of ovarian cancer patients (P = 0.0029), as measured by RT-PCR. The neutrophil-to-lymphocyte ratio, which is a prognostic biomarker of ovarian cancer, correlated with Th17 occupancy ratio in patients (P = 0.0068). We found that programmed cell death 1 ligand 1 expression and its associated factors (IL-6 and phospho-signal transducer and activator of transcription 3) were induced by IL-17 in an ovarian cancer cell line. These results suggest that increased Th17 counts and IL-17 level, which correlated with high neutrophil-to-lymphocyte ratio and programmed cell death 1 ligand 1 expression, are potential biomarkers for poor prognosis in ovarian cancer and likely indications for application of programmed cell death 1 ligand 1 pathway inhibitors., (© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2019
- Full Text
- View/download PDF
46. Mixed endometrioid and clear cell carcinoma arising from laparoscopic trocar site endometriosis.
- Author
-
Tsuruga T, Hirata T, Akiyama I, Matsumoto Y, Oda K, Fujii T, and Osuga Y
- Subjects
- Female, Humans, Middle Aged, Abdominal Neoplasms diagnosis, Abdominal Neoplasms etiology, Abdominal Neoplasms surgery, Adenocarcinoma, Clear Cell diagnosis, Adenocarcinoma, Clear Cell etiology, Adenocarcinoma, Clear Cell surgery, Carcinoma, Endometrioid diagnosis, Carcinoma, Endometrioid etiology, Carcinoma, Endometrioid surgery, Cell Transformation, Neoplastic, Endometriosis complications, Endometriosis diagnosis, Endometriosis etiology, Endometriosis surgery, Laparoscopy adverse effects, Ovarian Diseases diagnosis, Ovarian Diseases etiology, Ovarian Diseases surgery
- Abstract
Laparoscopic port site endometriosis is less common in abdominal wall endometriosis, and malignant transformation of abdominal wall endometriosis is rare. We reported a case of mixed endometrioid and clear cell carcinoma arising from port site endometriosis. The patient was a 49-year-old woman with a history of laparoscopic excision of ovarian endometrioma. Physical examination revealed a subcutaneous solid tumor around the laparoscopic surgical scar. Imaging showed a suspicious malignancy. She underwent radical marginal resection of the abdominal wall tumor, flap reconstruction of the abdominal wall, hysterectomy, bilateral salpingo-oophorectomy and omental biopsy. Histological examination revealed mixed endometrioid and clear cell carcinoma. Computed tomography scan showed no evidence of recurrence after six cycles of chemotherapy. This is the first case of malignant transformation from laparoscopic trocar site endometriosis., (© 2019 Japan Society of Obstetrics and Gynecology.)
- Published
- 2019
- Full Text
- View/download PDF
47. Management of a pregnant woman with hypouricemia: a case report.
- Author
-
Kumasawa K, Nakayama T, Hashimoto A, Kubota K, Takahashi Y, Furuya H, Shitara R, Seyama T, Tsuruga T, Iriyama T, Nagamatsu T, Osuga Y, and Fujii T
- Abstract
Renal hypouricemia is associated with urinary calculi and severe acute renal failure after exercise. The epidemiology of renal hypouricemia is not yet sufficiently understood, and there is no report of it occurring during pregnancy. We report the case of a pregnant woman with renal hypouricemia. At her first pregnancy, she developed preeclampsia with severe features at the 34th week of gestation. After parturition, she developed acute renal failure and was diagnosed with renal hypouricemia. During the second pregnancy, when she was referred to our hospital, care was taken to ensure adequate hydration by infusion of liquids and water at the time of labour. Consequently, she did not have onset of renal hypouricemia. We suggest that acute renal failure may be avoided in pregnant women with renal hypouricemia by preventing dehydration via drinking enough during pregnancy postpartum period and by infusion during labour.
- Published
- 2019
- Full Text
- View/download PDF
48. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
- Author
-
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, and Fujii T
- Subjects
- Adenocarcinoma, Clear Cell metabolism, Cell Line, Tumor, Cell Proliferation, Enhancer of Zeste Homolog 2 Protein metabolism, Female, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Histone-Lysine N-Methyltransferase metabolism, Histones metabolism, Humans, Ovarian Neoplasms metabolism, Repressor Proteins metabolism, Up-Regulation, Adenocarcinoma, Clear Cell genetics, Enhancer of Zeste Homolog 2 Protein genetics, Histone-Lysine N-Methyltransferase genetics, Ovarian Neoplasms genetics, Repressor Proteins genetics
- Abstract
Background: Wolf-Hirschhorn syndrome candidate gene-1 (WHSC1), a histone methyltransferase, has been found to be upregulated and its expression to be correlated with expression of enhancer of zeste homolog 2 (EZH2) in several cancers. In this study, we evaluated the role of WHSC1 and its therapeutic significance in ovarian clear cell carcinoma (OCCC)., Methods: First, we analyzed WHSC1 expression by quantitative PCR and immunohistochemistry using 23 clinical OCCC specimens. Second, the involvement of WHSC1 in OCCC cell proliferation was evaluated by MTT assays after siRNA-mediated WHSC1 knockdown. We also performed flow cytometry (FACS) to address the effect of WHSC1 on cell cycle. To examine the functional relationship between EZH2 and WHSC1, we knocked down EZH2 using siRNAs and checked the expression levels of WHSC1 and its histone mark H3K36m2 in OCCC cell lines. Finally, we checked WHSC1 expression after treatment with the selective inhibitor, GSK126., Results: Both quantitative PCR and immunohistochemical analysis revealed that WHSC1 was significantly overexpressed in OCCC tissues compared with that in normal ovarian tissues. MTT assay revealed that knockdown of WHSC1 suppressed cell proliferation, and H3K36me2 levels were found to be decreased in immunoblotting. FACS revealed that WHSC1 knockdown affected the cell cycle. We also confirmed that WHSC1 expression was suppressed by EZH2 knockdown or inhibition, indicating that EZH2 is upstream of WHSC1 in OCCC cells., Conclusions: WHSC1 overexpression induced cell growth and its expression is, at least in part, regulated by EZH2. Further functional analysis will reveal whether WHSC1 is a promising therapeutic target for OCCC.
- Published
- 2019
- Full Text
- View/download PDF
49. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
- Author
-
Kawata Y, Nagasaka K, Matsumoto Y, Oda K, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Arimoto T, Osuga Y, and Fujii T
- Subjects
- Adult, Aged, Aged, 80 and over, Ascites etiology, Ascites pathology, Body Temperature, Cell-Free System, Female, Humans, Middle Aged, Ovarian Neoplasms pathology, Retrospective Studies, Treatment Outcome, Ascites therapy, Ovarian Neoplasms complications
- Abstract
Background: The management of refractory ascites in advanced ovarian cancer (AOC) is vital for patients with abdominal distention, respiratory distress, and anorexia due to massive ascites with cancer peritonitis. We analyzed the benefits of concentrated ascites reinfusion therapy (CART) in the management of AOC., Methods: We reviewed records of AOC patients who underwent CART between January 2011 and March 2017. We retrospectively analyzed patients' backgrounds and physiological changes, including body weight, abdominal girth, urine volume, blood component values, blood pressure, heart rate, and body temperature before and after CART. We investigated the clinicopathological significance of CART by measuring the mean number of ascites tumor cell (ATC) clusters before CART., Results: A retrospective analysis was performed on 29 cases of AOC with massive ascites involving 47 CART sessions. The patients' mean age was 56.6 ± 12.8 years, and the mean number of sessions was 1.7 ± 1.2. The mean volume of the processed ascites was 2,937 ± 820 mL, which was concentrated to 272 ± 84 mL containing 85.0 ± 33.2 g protein on average. Significant reductions in abdominal girth (- 5.30 ± 0.65 cm; p < 0.0001) and body weight (- 2.97 ± 0.26 kg; p = 0.0011), increased urine volume (+ 824.29 ± 145.21 mL; p < 0.0001), and improved serum albumin levels (+ 0.18 ± 0.34; p < 0.0001) were observed after CART. Analysis of variance revealed significant elevations in body temperature after CART in 11 patients with a small number of ATC clusters., Conclusions: CART is useful for the therapeutic management of AOC patients with refractory massive ascites. Elevations of body temperature after CART may be avoided by the investigation of patients' peritoneal cytology before CART.
- Published
- 2019
- Full Text
- View/download PDF
50. Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients.
- Author
-
Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanikawa M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Yokota H, Osuga Y, and Fujii T
- Subjects
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Lymph Nodes pathology, Lymphatic Metastasis, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Proportional Hazards Models, Retrospective Studies, Survival Rate, Uterine Cervical Neoplasms pathology, Hysterectomy mortality, Lymph Node Excision mortality, Lymph Nodes surgery, Neoplasm Recurrence, Local surgery, Uterine Cervical Neoplasms surgery
- Abstract
Background: Although many studies have already shown that lymph node metastasis is one of the major prognostic factors for cervical cancer, the therapeutic significance of para-aortic lymphadenectomy for the surgical treatment of cervical cancer remains controversial., Methods: A total of 308 patients diagnosed with stage IB2, IIA2, or IIB cervical cancer and treated with radical hysterectomy were retrospectively investigated to assess the incidence of para-aortic lymph node metastasis and the clinicopathological factors linked to cervical cancer prognosis., Results: Para-aortic lymph node metastases were pathologically confirmed in 13 of the 136 patients (9.6 %) who underwent para-aortic lymphadenectomy. The incidence of para-aortic lymph node metastasis was significantly higher in the patients who had common iliac lymph node metastases (odds ratio 31.5, p < 0.001) according to logistic regression analysis. Common iliac lymph node metastasis was related to risk of recurrence (hazard ratio 2.43, p = 0.003) and death (hazard ratio 2.62, p = 0.007) in Cox regression analysis. Kaplan-Meier analysis and Cox regression analysis showed that para-aortic lymphadenectomy did not have a positive impact on survival in 308 patients or 140 pN1 patients, but para-aortic lymphadenectomy was related to better overall survival with a marginal trend toward significance (p = 0.053) in 30 patients with common iliac lymph node metastasis., Conclusions: Indication for para-aortic lymphadenectomy in the surgical treatment of stage IB2, IIA2, or IIB cervical cancer needs to be individualized. Patients with common iliac lymph node metastasis are possible candidates, and a prospective study is needed to clarify this issue.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.